Calidi Biotherapeutics Inc. Showcases Breakthrough in Cancer Treatment with Genetic Medicine Platform
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is pioneering a precision genetic medicine platform aimed at revolutionizing cancer treatment by targeting both primary and metastatic tumors with engineered viruses.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been featured in a NetworkNewsWire editorial for its innovative precision genetic medicine platform. This platform is designed to target both primary and metastatic cancer tumors using engineered viruses, offering a novel approach to cancer treatment. With global cancer diagnoses projected to rise to 35 million annually by 2050, Calidi's technology could address significant unmet needs in oncology. The company's method focuses on delivering potent genetic therapies directly to cancer sites, potentially transforming the landscape of cancer treatment.
The editorial highlights the urgency and importance of Calidi's work, given the increasing global burden of cancer. Calidi's stem cell-based platforms are engineered to carry oncolytic viruses, which are then used to treat various oncology indications, including high-grade gliomas and solid tumors. This approach not only aims to enhance the efficacy of cancer treatments but also to improve patient safety by protecting and amplifying the therapeutic viruses.
For more information on Calidi Biotherapeutics and its groundbreaking work, visit https://ibn.fm/wj9TN. Additional updates and news about CLDI can be found in the company's newsroom at https://ibn.fm/CLDI.